|
DAY 1 (June 17) |
|||
|
7:00 PM |
Conference Registration |
||
|
8:00 PM |
Welcome Reception and Dinner |
||
|
DAY 2 (June 18) |
|||
|
8:00 AM |
Breakfast |
||
|
8:50 AM |
Welcome and Opening Remarks John Lambris |
||
|
SESSION I |
Therapeutic complement modulation in severe COVID-19 Chairs: Carl Atkinson, Lisa Gralinski |
||
|
9:00 AM |
1 |
Targeting complement in COVID-19: where we stand and what lies ahead |
|
|
9:20 AM |
2 |
Regulation of Inflammation by local complement in COVID-19 Behdad Afzali |
|
|
9:40 AM |
3 |
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules Cecilia Garlanda |
|
|
10:00 AM |
4 |
Complement signaling mediates coronavirus-induced lung injury Lisa Gralinski, Ande West, Sarah Leist, and Ralph Baric |
|
|
10:20 AM |
5 |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein Matteo Stravalaci, Niloufar Kavian-Tesslar, Isabel Pagani, Hang Zong, Francesco Scavello, Barbara Bottazzi, Elisa Vicenzi, Alberto Mantovani, and Cecilia Garlanda |
|
|
10:35 AM |
6 |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19 Michael Hultström, Robert Frithiof, Jonathan Grip, Linnea Lindelöf, Olav Rooijackers, Sara Pigazzini, Mari Niemi, Mattia Cordioli, Lindo Nkambule, Tomislav Maricic, Kristina Nilsson Ekdahl, Bo Nilsson, Miklós Lipcsey, Hugo Zeberg, and Oskar Eriksson |
|
|
10:50 AM |
Coffee Break and Poster Viewing |
||
|
SESSION II |
Therapeutic development: novel complement inhibitors Chairs: Cecilia Garlanda, Antonio Risitano |
||
|
11:30 AM |
7 |
Taking C3 inhibition to the next level: new insights and clinical opportunities John D. Lambris |
|
|
11:50 AM |
8 |
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls Antonio M. Risitano, Regis Peffault de Latour, Luana Marano, Camilla Frieri, Dimitrios Mastellos, and John D. Lambris |
|
|
12:10 PM |
9 |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation Alexander McQuiston, Changhai Li, Zhenxiao Tu, Kunal Patel, Logan Langerude, Stephen Tomlinson, Carl Atkinson |
|
|
12:25 PM |
10 |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries Said Rabbani, Rachel Hevey, Martin Smiesko, Daniel Ricklin, and Roman Jacob |
|
|
12:40 PM |
11 |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury Anjan Bongoni, Ingela Vikstrom, Jennifer McRae, Evelyn Salvaris, Nella Fisicaro, Martin Pearse, Sandra Wymann, Tony Rowe, Adriana Bazmorelli, Peter Cowan, and Matthew Hardy |
|
|
12:55 PM |
12 |
Development and testing of super-functional Factor I-based constructs for multiple disease modalities Thomas Cox, Helena Thomas Eke, Jan Jensen, Thomas Hallam, Shyam Iyer, James McGuire, and Kevin Marchbank |
|
|
1:10 PM |
13 |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of inflammatory bowel disease Cedric Cui, Vinod Kumar, Xaria Li, Ning Liu, Richard Clark, Andrew Whittaker, Felicity Han, John Lee, and Trent Woodruff |
|
|
1:25 PM |
Lunch and Informal Discussions |
||
|
7:30 PM |
Dinner and Informal Discussions |
||
|
DAY 3 (June 19) |
|||
|
SESSION III |
Structural insights and mechanisms of activation, regulation and signaling crosstalk Chairs: Brian Geisbrecht, Veronique Fremeaux-Bacchi |
||
|
9:00 AM |
14 |
Structural insights into complement protease complexes Piet Gros |
|
|
9:20 AM |
15 |
Modified DNA aptamers as inhibitors of complement proteins and their complexes Brian Geisbrecht |
|
|
9:40 AM |
16 |
Activation of the complement system by cholesterol crystals Terje Espevik |
|
|
10:00 AM |
17 |
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors Henry Nording, Antje Luebken, Tobias Geisler, and Harald Langer |
|
|
10:15 AM |
18 |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I Alexandra Gerogianni, Jordan Dimitrov, Victoria Poillerat, Satheesh Chonat, Kerstin Sandholm, Karin McAdam, Kristina Ekdahl, Tom Mollnes, Camilla Mohlin, Lubka Roumenina, and Per Nilsson |
|
|
10:30 AM |
19 |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5 Henri Wedekind, Arno Fenske, Andreas Tiede, Birgit Weinhold, Anja Münster-Kühnel, and Markus Abeln |
|
|
10:45 AM |
20 |
The intertwined relationship between complement and platelet activation Harald Langer |
|
|
11:05 AM |
Coffee Break and Poster Viewing |
||
|
SESSION IV |
Complement in cancer: mechanistic insights and therapeutic concepts Chairs: Ruben Pio, Lubka Roumenina |
||
|
11:45 AM |
21 |
Complement-related therapies to treat cancer: where to target? Ruben Pio |
|
|
12:05 PM |
22 |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells Ronald P. Taylor |
|
|
12:25 PM |
23 |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours Monica Olcina |
|
|
12:40 PM |
24 |
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer Margot Revel |
|
|
12:55 PM |
25 |
Intracellular activation and regulation of the complosome - driver of cancer progression Alessandra Zarantonello, Margot Revel, Tania Robe-Rybkine, Antonin Bourdin, Catherine Sautes-Fridman, Wolf Herman Fridman, and Lubka Roumenina |
|
|
1:10 PM |
26 |
Complementome as a driver of (tumor) cell fate Lubka Roumenina |
|
|
1:25 PM |
Lunch and Informal Discussions |
||
|
7:30 PM |
Dinner and Informal Discussions |
||
|
DAY 4 (June 20) |
|||
|
SESSION V |
Complement in neuroinflammation and neurodegenerative diseases Chairs: Cynthia Lemere, B. Paul Morgan |
||
|
9:00 AM |
27 |
Targeting complement for therapy of neurodegenerative diseases B. Paul Morgan |
|
|
9:20 AM |
28 |
Global C3 lowering in adult mice protects against hippocampal aging Cynthia Lemere |
|
|
9:40 AM |
29 |
The contribution of the terminal pathway to disease progression in neurological disorders Frank Baas |
|
|
10:00 AM |
30 |
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation Katherine Given, Elizabeth Acker, and Jeffrey Bennett |
|
|
10:15 AM |
31 |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy Inge Van de Walle, Kevin Budding, Lill Johansen, Kim Dijkxhoorn, Elisabeth de Zeeuw, Lauri Bloemenkamp, Domenica Gandini, Olivier Van de Steen, Jeanette Leusen, Hans de Haard, C. Hack, and W. van der Pol |
|
|
10:30 AM |
32 |
Targeting novel anti-complement drugs to the brain for therapy of dementia Wioleta Zelek, Ryan Bevan, Maarten Dewilde, Bart De Strooper, and Bryan Morgan |
|
|
10:45 AM |
Coffee Break and Poster Viewing |
||
|
SESSION VI |
Complement targeting in ocular inflammation and hemolytic disorders Chairs: Gregory Hageman, Baerbel Rohrer |
||
|
11:30 AM |
33 |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment Gregory Hageman |
|
|
11:45 AM |
34 |
Elucidating the association between complement factor H-related 4 and age-related macular degeneration Moussa Zouache, Chris Pappas, Robert Anstadt, Jin Liu, Stacie Matthews, Jill Hageman, Burt Richards, and Gregory Hageman |
|
|
12:00 PM |
35 |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement Balasubramaniam Annamalai, Nathaniel Parsons, Crystal Nicholson, Elisabeth Obert, Bryan Jones, and Baerbel Rohrer |
|
|
12:15 PM |
36 |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration Claire Harris, James Francis, Eva Pekle, Sonal Varsani, Emanuela Gardenal, Kate Carney, Anna Dreismann, Luisa Mendonca, Darin Curtiss, Nadia Waheed, and Jane Hughes |
|
|
12:30 PM |
37 |
Sickle Cell Disease: a role for complement activation in organ injuries? Anne Grunenwald, Julie Peliconi, Elodie Voilin, Julien Lavergne, Margot Revel, and Lubka Roumenina |
|
|
12:45 PM |
Live poster session A: 5-min flash talks |
||
|
1:15 PM |
Lunch and Informal Discussions |
||
|
3:00 PM |
(CITY TOUR) |
||
|
7:30 PM |
Dinner and Informal Discussions |
||
|
DAY 5 (June 21) |
|||
|
SESSION VII |
Genetic drivers, mechanisms and targets in (auto)-immune and inflammatory diseases Chairs: George Hajishengallis, Monica Olcina |
||
|
9:00 AM |
38 |
TBD Markus Huber-Lang |
|
|
9:20 AM |
39 |
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease Samyr Kenno, Sina Borus, Katja Bieber, and Jörg Köhl |
|
|
9:40 AM |
40 |
Complement is required for microbe-driven induction of Th17 and periodontitis Hui Wang, Hidetaka Ideguchi, Tetsuhiro Kajikawa, Dimitrios Mastellos, John Lambris, and George Hajishengallis |
|
|
10:00 AM |
41 |
Lest we forget: Lessons from complement reactions to oligos, anti drug antibodies and AAV gene therapy Ashley Frazer-Abel |
|
|
10:15 AM |
42 |
Targeted Panels or Exome - Which is the Right NGS Approach for complement-mediated diseases? Veronique Fremeaux-Bacchi |
|
|
10:35 AM |
43 |
Clinical Xenotransplantation: Implications for Complement Inhibition Robert Montgomery |
|
|
10:55 AM |
44 |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease Jean Francis, Hamza Hassan, Josh Korzenik, Deepak Rao, Jennifer Ho, David Salant, and John Sloan |
|
|
11:10 AM |
Coffee Break and Poster Viewing |
||
|
SESSION VIII |
Complement: a multifaceted driver of thromboinflammation Chairs: Markus Huber-Lang, Wioleta Zelek |
||
|
11:45 AM |
45 |
Venous air embolism activates complement C3 without corresponding C5 activation and triggers thromboinflammation in pigs Benjamin Storm, Judith Ludviksen, Dorte Christiansen, Hilde Fure, Kristin Pettersen, Anne Landsem, Bent Nilsen, Knut Dybwik, Tonje Braaten, Erik Nielsen, and Tom Mollnes |
|
|
12:05 PM |
46 |
Complement-induced prothrombotic activation of platelets requires the lysis of cells Marco Mannes, Veronika Pechtl, Christoph Schmidt, Susanne Hafner, Vivek Manivel, Oskar Erkisson, Kristina Ekdahl, Bo Nilsson, John Lambris, and Markus Huber-Lang |
|
|
12:20 PM |
47 |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors Hailey Harris, Sanjay Khandelwal, Lubica Rauova, Douglas Cines, Brandon Garcia, and Gowthami Arepally |
|
|
12:35 PM |
48 |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood Ole Brekke, Joost Grond, Anne Landsem, Dorte Christiansen, Judith Ludviksen, Corinna Lau, Trent Woodruff, John Lambris, Terje Espevik, and Tom Mollnes |
|
|
12:50 PM |
49 |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation Bo Nilsson, Alireza Biglarnia, Kristina Ekdahl, Marianne Jensen, and Yuji Teramura |
|
|
1:10 PM |
Live poster session B: 5-min flash talks |
||
|
1:40 PM |
Closing remarks John Lambris |
||
|
1:45 PM |
Lunch and Informal Discussions |
||
|
8:00 PM |
Farewell dinner |
||
|
DAY 6 (June 22) |
|||
|
8:00 AM |
Breakfast |
||
|
Departure |
|||
POSTERS
This year the conference program will include two live poster sessions in which participants interested in showcasing the main findings of their study ‘in a nutshell’ will have the opportunity to deliver a 5-min ‘flash’ talk to the audience:
1. Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Linnea Lindelöf, David Eikrem, Kristina Nilsson Ekdahl, Peter Garred, Bo Nilsson, and Oskar Eriksson
2. Role of pentraxin 3 and interaction with complement in immune defence against malaria
Hang Zhong
3. Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
Elod Kortvely, Antonello Caruso, Jannik Vollmer, Matthias Machacek, and Robin Denhardt-Eriksson
4. Fragment-based drug design in the development of novel inhibitors against the initiating protease, C1r, of the classical pathway of complement
Denise Rohlik
5. Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Ellen Millman, Daniel Mills, Oksana Shkilnyk, Dieudonne Sidi, Michelle Elvington, Tobin Cammett, and Martin Schmidt
6. A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
Gerald Cox, Chin Meng Khoo, Charlene Song, and Judith Wu
7. Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Sandra Wymann, Marcel Mischnik, David Leong, Subhajit Ghosh, Xiahui Tan, Helen Cao, Benjamin Kuehnemuth, Glenn Powers, Partho Halder, Mitchell de Souza, Hannah James, Vesna Tomasetig, Holger Lind, Paolo Rossato, Catherine Owczarek, Saw Yen Ow, Steven Dower, Adriana Baz Morelli, Tony Rowe, and Matthew Hardy
8. The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
Agnieszka Belter, Anna-Maria Barciszewska, and Miroslawa Naskt-Barciszewska
9. Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Beatrice Fageräng, Corinna Lau, Pedro Coelho Medeiros, Karin Mc Adam, Camilla Schjalm, Per Nilsson, Peter Garred, and Tom Eirik Mollnes
10. Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Pedro Miguel Coelho Medeiros, Leon Cyranka, Anne Rosbjerg, Camilla Schjalm, Peter Garred, Reinhard Wuerzner, and Tom Eirik Mollnes
11. Complement implication in the acute kidney injury associated with rhabdomyolysis
A Grunenwald, V Poillerat, M Revel, E Voilin, T Robe-Rybkine, I Boudhabhay, S Sacks, Florent Petitprez, L Gilardin, LT Roumenina
12. Measuring C5a with functional bioassay
Michael Schwenkert and Ali Qamar
13. Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
Sarika Agarwal, Troy Gilliam, and Patrick Sexton